GoKawiilIntellia's in-body CRISPR therapy shows lasting effect after four years
Intellia Therapeutics has released four-year follow-up data showing its gene-editing therapy lonvoguran ziclumeran continues to suppress a protein that triggers hereditary angioedema attacks. The treatment uses CRISPR-Cas9 delivered directly into the body to disable the gene producing prekallikrein, rather than editing cells outside the body as with existing therapies. Intellia has filed for FDA approval, with a decision expected by 10 March.